LTRN
Lantern Pharma Inc. (LTRN) Business Model Analysis (2026)
Overall Score
Revenue Model
No meaningful revenue base is evident in the TTM metrics, with revenue per share at 0 and price-to-sales at 0.
The business remains unprofitable, with net profit margin, EBIT margin, and EBITDA margin all at 0 in the provided ratios.
Profitability
TTM returns remain deeply negative, including ROA of -2.17%, ROE of -4.56%, and ROIC of -3.58%.
Operating profitability is still negative, with operating return on assets at -1.95% and EBITDA/EBIT margins at 0.
Balance Sheet
Liquidity is acceptable, with a current ratio of 1.96 and cash ratio of 1.54.
Leverage appears low on a market-cap basis, with debt-to-assets at 0.46% and debt-to-market-cap at 0.16%, though equity and book value remain negative.
Cash Flow
Cash generation is still negative, with operating cash flow per share at -1.13 and free cash flow per share at -1.13.
Cash flow yields remain negative, including free cash flow yield of -0.57% and operating cash flow ratio of -3.26.
Valuation
Traditional valuation multiples are not meaningful or remain distorted, with negative P/E, negative price-to-book, and negative enterprise value multiples.
The market is still pricing the company at a very small enterprise value of about $18.0M versus a market cap of about $24.6M, but this reflects distress rather than clear undervaluation.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

